F-star Therapeutics in Licensing Deal with AstraZeneca; Shares Up
July 08 2021 - 8:46AM
Dow Jones News
By Michael Dabaie
F-star Therapeutics Inc. said it is in an exclusive licensing
agreement with AstraZeneca PLC, sending shares higher
premarket.
AstraZeneca will receive global rights to research, develop and
commercialize next generation Stimulator of Interferon Genes, or
STING, inhibitor compounds. F-star is a clinical-stage
biopharmaceutical company focused on bispecific immunotherapies for
cancer.
AstraZeneca will be responsible for all future research,
development and commercialization of the STING inhibitor compounds,
and F-star will retain rights to all STING agonists, currently in
clinical development for patients with cancer.
F-star is eligible to receive upfront and near-term payments of
up to $12 million. F-star can also receive development and sales
milestone payments of more than $300 million, as well as single
digit percentage royalty payments.
F-star shares were up 8% to $7.95 premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 08, 2021 08:43 ET (12:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
